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Aggregationa-Synuclein is found in plaques associated with Parkinson’s and other neurodegenerative diseases.
Changes in a-synuclein oligomerization are thought to give rise to nucleation of neurodegenerative
plaques. Here, we investigated the effect of hydrostatic pressure on the aggregation of a-synuclein
in cultured neuronal cells. We found that hydrostatic pressure is associated with a transition from
monomeric to higher order a-synuclein aggregates. We then tested whether this aggregation is
associated with the loss of binding partners, such as phospholipase Cb. We found that increased
pressure reduces the level of PLCb1 and the amount of a-synuclein/PLCb1 complexes. These studies
suggest that pressure promotes release of a-synuclein from protein partners promoting its
oligomerization.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Many neurodegenerative diseases, such as Parkinson’s, Mutiple
System Atrophy, Dementia with Lewy Bodies, and Amyotrophic
Lateral Sclerosis, are caused by protein aggregates composed
largely of the protein a-synuclein (AS). This group of neurodegen-
erative diseases, referred to as Lewy Body Diseases are found in
patients that carry point mutations or multiple copies of the AS
gene [1–9]. However, genetic mutations of AS account only for a
small percentage of pathologies and two major environmental
causes linked to sporadic LBD have been identified. One is
traumatic brain injury (TBI) caused by acute force and pressure,
followed by prolonged increased inter-cranial pressure. In neurons,
this increased pressure affects the conformations and interactions
of proteins which can lead to cell death [10–14].
AS is a small (140kDa) cytosolic protein that is abundant in the
central nervous system, and conserved in vertebrates [1,15]. AS has
been classified as a ‘natively unstructured’ protein [16]. However,
under certain conditions, AS becomes helical and self-associates
to a tetramer [17,18]. At high concentrations, AS forms fibrilswhich resemble the structures found in Lewy bodies. AS might also
function as a ‘prion’ and internalize into neighboring neurons and
further promote aggregation [19,20].
The cellular function of AS is unknown. Its high degree of
conservation and abundance in neuronal tissue suggests that it
plays some critical role. Studies of AS knock-out mice show a
variety of neurological abnormalities that are difficult to interpret.
Molecular-based studies suggest that AS can potentially bind many
different partners that are primarily associated with lipid signaling
and vesicle recycling [21]. Our lab has found that AS binds to the
G-protein regulated enzyme phospholipase Cb (PLCb) with an
affinity 10 times stronger than other reported protein partners
[22]. Binding of AS to PLCb alters its ability of hydrolyze signaling
lipids and changes Ca2+ signaling in cells [22–26].
Because of the importance of AS in neurodegeneration, there
have been many studies to delineate its cellular function, but no
clear picture has emerged. Based on our work and the work of
others, we proposed that AS does not have an intrinsic activity
but rather modifies and optimizes cell function via interactions
with other proteins [27]. Any stress that releases AS from its bind-
ing partners, such as oxidation or pressure, will result in AS aggre-
gation and lead to cell death. In a recent study, we subjected cells
to an oxidizing environment [26] that resulted in the loss of many
cellular proteins including PLCb while the cellular level of AS was
not affected [26]. The decrease in PLCb level promoted homo-
oligomerization of released AS. Moreover, down-regulating PLCb
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AS aggregation.
It has been established that subjecting protein complexes to
pressure, including AS fibrils, forces solvent into the void regions
between the subunits resulting in disassembly [28,29]. Based on
this observation, we propose that increased cranial pressure results
in dissociation of AS from PLCb, and other cell components that
prevent its aggregation. The release of AS may then lead to
oligomerization and ultimately, disruption of cell function (see
[30]). In this study, we have tested this idea in cultured neuronal
cells (PC12 and SK-N-SH) under hydrostatic pressure.2. Materials and methods
2.1. Cell culture and transfection
SK-N-SH and PC12 cells were obtained from ATCC (HTB-11,
CRL-1721). SK-N-SH cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum, 50 units/ml penicillin, and 50 lg/ml streptomycin sulfate.
PC12 cells were cultured in DMEM medium supplemented with
10% horse serum, 5% fetal bovine serum, 50 units/ml penicillin,
and 50 lg/ml streptomycin sulfate. Cells were kept at 37 C with
5% CO2. Plasmids were introduced at 80–90% confluency using
Lypophectamine2000TM according to the manufacturer specifica-
tions. In general 1 lg of DNA was used for 10 ll of Lypophec-
tamine2000TM. Cells were transfected in serum free Opti-MEM
medium and the medium was replaced with full growth medium
after 5–7 h. Cells were imaged 48–72 h post transfection in phenol
free Leibowitz15 (L15) medium.2.2. Western blotting
Cells were lysed on ice for 20 min. Lysates were subjected to
SDS–PAGE using 12% polyacrylamide gels, followed by the transfer
to a nitrocellulose membrane. The membrane was then incubated
for 1 h with 5% non-fat dry milk dissolved in Tris–buffered saline
with 0.5% Tween (TBST) to block the non-specific binding. The
primary antibody (mouse anti AS, rabbit anti PLCb1), diluted
according to the manufacturer’s instructions, was added to the
membrane and incubated for 1 h. This was followed by 3 washes
of 15 min each in TBST. After the addition of horseradish
peroxidase-conjugated secondary antibody for 1 h, the membrane
was washed 3 times for 15 min each in TBST. The membrane was
subjected to imaging after a chemiluminescence reaction (Pierce,
Inc., Rockford, IL, USA).2.3. In vivo single cell Föster resonance energy transfer (FRET)
FRET experiments were performed on Zeiss LSM 510 Meta/
confocor2 apparatus (Jena, Germany) using synthesized emission
method. We used a 40  NA 1.2 C-Apochromat water immersion
objective and following filter settings: GFP excitation: 488 nm line
of argon ion laser and emission: 500–550 nm band pass filter,
mCherry excitation: 543 nm line of HeNe laser and emission:
585–615 nm band pass filter, and FRET excitation: 488 nm and
emission: 585–615 nm band pass filter. Bleed through from GFP
fluorescence into the FRET channel and direct excitation of
mCherry by the 488 nm laser line values were estimated from cells
transfected with GFP-PLCb1 and mCherry -AS separately and
imaged under the appropriate filter sets. The negative control FRET
value was determined from cells transfected with GFP-PLCb1 and
mCherry-vector. After background subtraction NFRET values were
calculated for every pixel in the image according to formula:NFRET ¼ IFRET  a IeGFP  b ImCherryﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
IeGFP  ImCherry
p
where a is the percentage of bleed-through of GFP through FRET
filter set and b is the percentage of direct excitation of mCherry by
488 nm light [31].
2.4. Number and brightness (N&B)
PC12 cells were transfected with GFP-AS, subjected to hydro-
static pressure, plated in glass bottom chambers and allowed to
recover for 24 h. Confocal images were collected on an Olympus
Fluoview 1000 LSCM fitted with a 60 PlanApo (1.40 NA) oil
immersion objective. The analog/digital hybrid detector (PMT)
was used in photon counting mode with 1 gain and 0% offset.
Images of cells were collected with resolutions of 66 nm/pixel. A
region of interest (256  256 box or 128  128 box) was analyzed
from an image of 320  320 pixels. The pixel dwell time was
4 ls/pixel and the pinhole diameter was 200 lm. GFP was excited
with the 0.1% of 488-nm line of a 40 mW argon ion laser. In general
100 images of one cell were collected. Data analysis was done
using the N&B analysis screen of the SimFCS program (www.lfd.
uci.edu). The offset and the readout noise were determined from
the histograms of dark counts performed after every 10 measure-
ments (100 images collected with the laser turned off) [32].
2.5. Statistical analysis
For statistical analysis we used SigmaPlot13 (SPSS, INC., Chicago,
IL). We compared the values of NFRET and N&B using
Kruskal–Wallis One Way Analysis of Variance on Ranks, Dunn’s
Method, One Way Analysis of Variance, Tukey’s Method, and t-test.
We concluded the values are significantly different when P < 0.05.
3. Results
3.1. Overview of pressure studies
We first carried out preliminary studies to determine the
amount of hydrostatic pressure that could be applied to cultured
cells without a large loss in viable cells. We found that the
neuronal cultured cell lines used in this study, human SK-N-SH
and rat PC12, cells could withstand hydrostatic pressures of 1000
bars (comparable to the deepest point in the Pacific Ocean, and
the highest pressure tested) for at least an hour with only a small
fraction of the population lost. We note that pressure-treated cells
attached identically to growth chambers as untreated cells and
displayed normal morphology, growth and mitochondria.
In all studies, we subjected cells to either 500 or 1000 bars at
room temperature (both gave identical results) by suspending
the cells in medium, placing into a pressure chamber (see [33])
increasing the pressure over a 3–5 min period, incubating for a
specific period of time, slowly releasing the pressure, plating the
cells in chambers in growth medium, and allowing them to recover
for 24 h. In all studies, control cells were treated identically except
they were not pressurized.
3.2. Increased hydrostatic pressure promotes aggregation of
intracellular endogenous AS
The level of AS aggregation of pressurized samples was
analyzed by Western Blotting. The data for PC12 cells (Fig. 1A)
show that pressure treatment results in higher molecular weight
AS bands that correspond to a tetramer. Identical results were
obtained for SK-N-SH cells and PC12 cells. We repeated the
measurements multiple times with similar results.
Fig. 1. Western blots of AS and PLCb1 in PC12 cells treated with pressure. (A) PC12
cells were subjected to 1000 bars for 1 h, plated in growth medium and allowed to
recover for 24 h. Control samples were kept at room temperature in identical
chambers as the pressurized sample. Western blotting was carried out as described
in Section 2. Pressure-treated samples showed a band at a molecular weight
corresponding to a tetramer (marked with an arrow). (B) Pressure treated samples
as in A were probed with rabbit anti PLCb1. The blot shows two independent
experiments. Two right columns are from the same lysates as in A. In both cases
pressurized samples have significantly lower amount of PLCb1.
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PLCb1
We hypothesized that the reason for increased aggregation of
a-AS in pressure treated cells is the disappearance of binding
partners. To test that possibility we analyzed pressure treated cell
lysates for the presence of its binding partner PLCb1. Pressure-
treated PC12 cells were subjected to SDS–PAGE followed by
western blotting. In Fig. 1B we show that pressure treated cells
had reduced levels of PLCb1 (the membrane was stripped and
re-probed for AS to confirm its aggregation). The studies were
repeated three times under similar conditions and at reduced
pressure and exposure times and similar results we obtained.
3.4. Increased hydrostatic pressure reduces binding between AS and
PLCb1
To test whether increased hydrostatic pressure disrupts the
interaction between AS and PLCb1, we performed FRET measure-
ments between GFP-labeled PLCb1 and mCherry-labeled AS. PC12
cells were transfected for 24 h before pressurization. In Fig. 2, we
show that the normalized FRET (NFRET) between GFP-PLCb1 andFig. 2. Changes in PLCb1-AS FRET in PC12 cells treated with pressure. Samples cells
were transfected with GFP-PLCb1 and mCherry-AS; Control cells were transfected
with GFP-PLCb1 and mCherry vector. 24 h post transfection cells were treated with
1000 bars for 1 h, plated in growth medium and imaged 24 h later. Distributions of
NFRET values of pressure treated and control cells are shown in a box plot. The box
represents 25th and 75th percentile, the line in the box represents median, and the
whiskers represent 10th and 90th percentile. NFRET values of GFP-PLCb1 and
mCherry-AS for pressure treated samples and control are 0.285 ± 0.006, n = 70 and
0.325 ± 0.006, n = 63, respectively. The difference is statistically significant
P < 0.001. The NFRET values of GFP-PLCb1 and mCherry alone for pressure and
control are 0.250 ± 0.008, n = 22 and 0.261 ± 0.011, n = 19.mCherry-AS is significantly lower in the pressure-treated PC12
cells than in the untreated cells (pressure NFRET = 0.285 ± 0.006,
n = 70; control NFRET = 0.325 ± 0.006, n = 63; P < 0.001). There
was no change in signal between GFP-PLCb1 and mCherry alone
(pressure 0.250 ± 0.008, n = 22; control 0.261 ± 0.011, n = 19).
These results show that pressure induces a loss in PLCb1-AS asso-
ciation from 14.0 to 6%.
3.5. Increased hydrostatic pressure increases aggregation of GFP-AS
To corroborate our Western Blot studies, we assessed the aggre-
gation of AS in PC12 cells transfected with GFP-AS by N&B analysis.
This method follows the number of photons associated with a dif-
fusing species and can report on the oligomerization state. Cells
were transfected with GFP-AS and half were subjected to pressure
while the others used as controls. Next, the cellswere plated in glass
bottom dishes and N&B measurements were performed 24 h later.
Fig. 3 shows that cells that were subjected to pressure had a higher
value of Brightness as compared to untreated controls (brightness =
6.1 ± 0.3 * 104 counts/molecule/s with pressure (n = 41) and
4.6 ± 0.2 * 104 counts/molecule/s, control (n = 40), P < 0.013). These
values can be compared to monomeric GFP controls in transfected
PC12 cells (GFP with pressure: 4.1 ± 0.1 104 counts/molecule/s,
n = 28 and GFP control: 4.3 ± 0.2 104 counts/molecule/s, n = 38).
These results show that pressure induces AS aggregation.
4. Discussion
In this study, we show that subjecting neuronal cells to acute
high pressure results in aggregation of AS. This result sharply con-
trasts the behavior seen using purified AS [28,29]. This aggregation
was seen despite allowing the cells to recover for extended periods
of time. In trying to understand the mechanism that underlies
aggregation, we measured the loss of one of AS’s binding partners,
PLCb1. Similar to the effects seen for cells subjected to oxidation,
we find that the application of pressure reduces the association
between PLCb1 and AS most likely due to a loss in the cellular
content of PLCb1 as seen by western blotting. Dissociation of
protein aggregates is commonly seen in pressure studies [33].
The increased AS aggregation is consistent with dissociation of
AS-protein heterodimers and loss of AS binding partners.Fig. 3. Changes in GFP-AS in PC12 cells treated with pressure. PC12 cells were
transfected with GFP-AS or GFP vector, 24 h post transfection cells were treated
with 1000 bars for 1 h, plated in growth medium and imaged 24 h later. The box
plot (see above) represents distribution of the brightness per molecule per second.
Brightness of the pressure and control samples is 6.1 ± 0.3 * 104 counts/molecule/s,
n = 41 and 4.6 ± 0.2 104 counts/molecule/s, n = 40 respectively. The difference is
statistically significant P < 0.013. Brightness of GFP controls in transfected PC12
cells with pressure: 4.1 ± 0.1 104 counts/molecule/s, n = 28 and control: 4.3 ± 0.2
104 counts/molecule/s, n = 38.
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is quite variable but may very high in some cases. However,
intracranial pressures are far lower than the pressure used here,
but have a longer duration. Because cultured cells will not survive
well in the pressure chamber for extended periods, we subjected
cells to very high pressure for short period of time but stress that
it is unclear how these pressures compare to those experienced
during injury. We note that the pressures used here are experi-
enced by biological organisms under extreme conditions.
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